- Initiated Phase 1/2 triple combination study to accelerate the direct evaluation of the DNAM axis hypothesis
- Enrollment in COM701 Phase 1 monotherapy expansion cohort and Phase 1 COM902 dose escalation studies on track
PR Newswire
HOLON, Israel, Nov. 5, 2020